Press Releases

Trevena Announces Early Completion of Enrollment of Phase 2a/b Study of TRV130 in Postoperative Pain

Trevena Enters into $35 Million Tranched Term Loan Credit Facility

Trevena Appoints Adam M. Koppel to the Board of Directors

Trevena Granted Key U.S. Composition of Matter Patent for TRV130

Trevena Reports Second Quarter 2014 Financial Results

Trevena CEO to Present at the Canaccord Genuity 34th Annual Growth Conference

Trevena Initiates Phase 1 Multiple Ascending Dose Study of TRV734 for Acute and Chronic Pain

Trevena to Host Conference Call to Discuss Second Quarter 2014 Results on August 12

Trevena Granted Key U.S. Method of Use Patent for TRV027

Trevena Appoints Julie H. McHugh and Barbara Yanni to the Board of Directors